» Articles » PMID: 34885113

Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2021 Dec 10
PMID 34885113
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Non-Hodgkin lymphoma (NHL) is the third most common malignancy diagnosed in children. The vast majority of paediatric NHL are either Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), anaplastic large cell lymphoma (ALCL), or lymphoblastic lymphoma (LL). Multi-agent chemotherapy is used to treat all of these types of NHL, and survival is over 90% but the chemotherapy regimens are intensive, and outcomes are generally poor if relapse occurs. Therefore, targeted therapies are of interest as potential solutions to these problems. However, the major problem with all targeted agents is the development of resistance. Mechanisms of resistance are not well understood, but increased knowledge will facilitate optimal management strategies through improving our understanding of when to select each targeted agent, and when a combinatorial approach may be helpful. This review summarises currently available knowledge regarding resistance to targeted therapies used in paediatric anaplastic lymphoma kinase (ALK)-positive ALCL. Specifically, we outline where gaps in knowledge exist, and further investigation is required in order to find a solution to the clinical problem of drug resistance in ALCL.

Citing Articles

Challenges in utilizing ALK expression to distinguish primary cutaneous from systemic anaplastic large cell lymphoma.

Gleason L, Afifi L, Banner L, Talasila S, Joffe D, Bhatti S Mol Clin Oncol. 2024; 20(5):35.

PMID: 38596625 PMC: 11002836. DOI: 10.3892/mco.2024.2733.


Pathobiology of nodal peripheral T-cell lymphomas: current understanding and future directions.

Bisig B, Savage K, de Leval L Haematologica. 2023; 108(12):3227-3243.

PMID: 38037800 PMC: 10690915. DOI: 10.3324/haematol.2023.282716.


MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF.

Kondo N, Utsumi T, Shimizu Y, Takemoto A, Oh-Hara T, Uchibori K JCI Insight. 2023; 8(24).

PMID: 37917191 PMC: 10807714. DOI: 10.1172/jci.insight.173688.


Genomic profiling for clinical decision making in lymphoid neoplasms.

de Leval L, Alizadeh A, Bergsagel P, Campo E, Davies A, Dogan A Blood. 2022; 140(21):2193-2227.

PMID: 36001803 PMC: 9837456. DOI: 10.1182/blood.2022015854.


The New Treatment Methods for Non-Hodgkin Lymphoma in Pediatric Patients.

Derebas J, Panuciak K, Margas M, Zawitkowska J, Lejman M Cancers (Basel). 2022; 14(6).

PMID: 35326719 PMC: 8945992. DOI: 10.3390/cancers14061569.

References
1.
Bai R, Dieter P, Peschel C, Morris S, Duyster J . Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol Cell Biol. 1998; 18(12):6951-61. PMC: 109278. DOI: 10.1128/MCB.18.12.6951. View

2.
Gambacorti-Passerini C, Mussolin L, Brugieres L . Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib. N Engl J Med. 2016; 374(1):95-6. DOI: 10.1056/NEJMc1511045. View

3.
De Wispelaere W, Annibali D, Tuyaerts S, Lambrechts D, Amant F . Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?. Cancers (Basel). 2021; 13(9). PMC: 8122870. DOI: 10.3390/cancers13092040. View

4.
Huber R, Hansen K, Paz-Ares Rodriguez L, West H, Reckamp K, Leighl N . Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. J Thorac Oncol. 2019; 15(3):404-415. DOI: 10.1016/j.jtho.2019.11.004. View

5.
Ross-Macdonald P, Walsh A, Chasalow S, Ammar R, Papillon-Cavanagh S, Szabo P . Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC. J Immunother Cancer. 2021; 9(3). PMC: 7931766. DOI: 10.1136/jitc-2020-001506. View